Independent register of U.S. FDA drug recalls · updated Oct 11, 2026
RxRecalls Get alerts

Class II drug recalls - moderate risk

Class II means the product may cause temporary or medically reversible harm, and serious harm is unlikely. It is by far the largest recall class - most potency, dissolution and labeling problems land here.

14,535 recalls, newest first.

Class II · Moderate risk

Atorvastatin Calcium Tablets

Presence of Foreign Tablets/Capsules: A Carbamazepine Extended-Release 400 mg tablet was found in a 1000-count bottle of Atorvastatin Calcium Tablets, USP 40 mg.

Terminated Particulate / foreign matter Nivagen Pharmaceuticals Inc D-0001-2025
Class II · Moderate risk

Pluvicto

CGMP deviations

Ongoing cGMP deviation Advanced Accelerator Applications USA, Inc. NDC 69488-0010-61 D-0007-2025
Class II · Moderate risk

Refresh P.M.

Lack of Assurance of Sterility: The impacted lots may contain a breach in the tube seal.

Ongoing Sterility / contamination AbbVie Inc. D-0664-2024
Class II · Moderate risk

Hylenex recombinant

cGMP Deviations: Temperature excursion

Terminated Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 18657-117-04 D-0116-2025
Class II · Moderate risk

First Aid Antiseptic Ointment

Incorrect/Undeclared Excipients: The inactive ingredients labeled on the product boxes and tubes are listed as "mineral oil , petrolatum ". The inactive ingredients in the actual product are polyethylene glycol 400 , polyethylene glycol 4000.

Ongoing Chemical / undeclared Zhejiang Jingwei Pharmaceutical Co., Ltd. D-0013-2025
Class II · Moderate risk

Cefixime for Oral Suspension USP

Subpotent Drug- An out of specification ( OOS ) result observed in assay test during 18-month long term stability study.

Terminated Wrong potency / content Lupin Pharmaceuticals Inc. NDC 68180-405-01 D-0648-2024

Recalls by year